[back] [next] [content]

������������������

DIABETES PREVENTION TRIAL FINDINGS�����������

���� The Diabetes Prevention Trial ‑ Type 1 is a multi‑

center study of ways in which the onset of type 1 diabetes

might be prevented, delayed, or minimized.� One of the

hypotheses tested was whether "oral tolerization," oral

administration of insulin not to control blood sugar but to

"distract" the autoimmune attack on the pancreatic Beta

cells, might measurably slow the onset of diabetes.

����

���� The results have begun to come in.� A French medical

team tested 131 antibody‑positive diabetic patients, age 7‑

40, within two weeks of their diagnosis.� Participants were

randomly assigned 2.5mg of oral insulin, 7.5mg of oral

insulin, or placebo, for a period of one year.

�

���� Findings strongly disproved the tested hypothesis ‑‑

A1c results and other tests were similar in all three

groups.� The researchers interpret the results as follows:

Oral insulin, administered (in these dosages) at clinical

onset of type 1 diabetes, intended to slow or halt further

autoimmune attack on the pancreatic Beta cells, did not

prevent the further deterioration of Beta cell function.

[back] [next] [content]

�����������